| ²é¿´: 458 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
dylfgsľ³æ (ÖøÃûдÊÖ)
ÖÐÀɽ«
|
[ÇóÖú]
Óï·¨ÇóÖú
|
||
|
?¡ãCAPE-NO2 (1.5-12????) concentration-dependently inhibited platelet aggregation (Fig. 2) consistent with CAPE which suppressed platelet aggregation in a dose-dependent manner ?? ?¡À ?????????¡ã????????¡¤¡§???????? [ ??¡Á???¡Á¨¦ ?¨²????????¡Á? ] |
» ²ÂÄãϲ»¶
269Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ28È˻ظ´
267Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ6È˻ظ´
314Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¿ó´ó£¬²ÄÁϹ¤³Ìר˶314·Ö£¬0856¿Éµ÷¶¼¿ÉÒÔ
ÒѾÓÐ10È˻ظ´
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ31È˻ظ´
Ò»Ö¾Ô¸211 0703»¯Ñ§ 346·ÖÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´

xux730
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 86
- Ó¦Öú: 1719 (½²Ê¦)
- ½ð±Ò: 10740.4
- É¢½ð: 50
- ºì»¨: 43
- Ìû×Ó: 2947
- ÔÚÏß: 336.5Сʱ
- ³æºÅ: 1374299
- ×¢²á: 2011-08-20
- רҵ: ϸ°ûÖÜÆÚÓëµ÷¿Ø
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
dylfgs(RXMCDM´ú·¢): ½ð±Ò+5, ×î¼Ñ´ð°¸£¡»¶Ó³£À´£¡ 2014-01-05 00:16:47
RXMCDM: ·ÒëEPI+1 2014-01-05 00:16:53
dylfgs(RXMCDM´ú·¢): ½ð±Ò+5, ×î¼Ñ´ð°¸£¡»¶Ó³£À´£¡ 2014-01-05 00:16:47
RXMCDM: ·ÒëEPI+1 2014-01-05 00:16:53
|
CAPE-NO2 inhibited platelet aggregation in a concentration-dependent manner (1.5-12¦Ì¦¬) (Fig. 2), which was consistent with that CAPE suppressed platelet aggregation in a dose-dependent manner. ËÆºõ¸Ã¾ä×Ó¿ÉÒÔ¼òд³É£º As with CAPE, CAPE-NO2 inhibited platelet aggregation in a concentration-dependent manner (1.5-12¦Ì¦¬) (Fig. 2). |
3Â¥2013-10-11 08:23:15
befair
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 112
- Ó¦Öú: 131 (¸ßÖÐÉú)
- ½ð±Ò: 12333.8
- ºì»¨: 20
- Ìû×Ó: 661
- ÔÚÏß: 608.6Сʱ
- ³æºÅ: 2651461
- ×¢²á: 2013-09-13
- ÐÔ±ð: GG
- רҵ: ºê¹Û¾¼Ã¹ÜÀíÓëÕ½ÂÔ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-05 00:16:27
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-05 00:16:27
|
²»ÊÇ×öÕâ¸öרҵµÄ£¬Òò¶ø²»Ã÷°×CAPE-NO2»òÕßCAPE£¬µ«´ÓÉÏÏÂÎÄÀí½âÁËÖ÷ÒªÒâ˼,¼´Ç°Õßͨ¹ýŨ¶È±ä»¯À´ÒÖÖÆÑªÐ¡°å¾Û¼¯£¬ÕâºÍºóÕßͨ¹ý¼ÁÁ¿±ä»¯À´´ïµ½Í¬ÑùµÄЧ¹ûÊÇÒ»Öµġ£Òò´Ë½¨ÒéÐÞ¸ÄÈçÏ£º ¡°CAPE-NO2 (1.5-12¦Ì¦¬) inhibited platelet aggregation (Fig. 2) by varying the concentration and this is consistent with CAPE which did the same in a dose-dependent manner" 1. ÓÃconcentration-dependently inhibited¡£¡£¡£Òâ˼ͨµ«²»ÈçÓüòµ¥µãµÄ´Ê×é/¶ÌÓï by varying the concentration 2. inhibit ÊÇÖ¸²»Èᣡ£¡£·¢Éú»òÕßÈÃÆä±ä»º¶øsuppress ÊÇÈã¨ÒѾ¿ªÊ¼µÄ£©²»ÔÙ¼ÌÐø¡£¸öÈËÀí½âÂ¥Ö÷ËäÈ»ÓÃÁËÕâÁ½¸ö²»Í¬µÄ´Ê£¬µ«Ã²ËÆÏë˵µÄËÆºõÊÇͬһ¸öÒâ˼¡£Èç¹ûÊÇÕâÑù£¬ÇëÑ¡ÔñÒ»¸ö¡£ 3. ÔÎÄÓÃÁ½¸öÖØ¸´µÄ platelet aggregation²»ºÏÊÊ£¬¿ÉÒÔ¿¼ÂÇÔÚºó°ë¾äÖÐÓôú´Ê¡£ Ï£ÍûÓаïÖú |

2Â¥2013-10-10 18:17:14













»Ø¸´´ËÂ¥